NANJING , China , July 18, 2022 /PRNewswire/ -- On July 13 2022, Simcere Pharmaceuticals (02096.HK) announced that the China National Medical Products Administration (NMPA) has conditionally approved COSELA® (trilaciclib hydrochloride for injection), an innovative myeloprotection drug jointly developed in China by Simcere and G1 Therapeutics. The product is approved to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer.
A'Bullet-Proof Vest' for the Bone Marrow
Chemotherapy has been considered the cornerstone in the treatment of many types of cancer. It is predicted that by 2040, the number of new cancer patients requiring chemotherapy in China will reach 4.2 million. However, the incidence of toxic side effects caused by chemotherapy is extremely high, which has a profound impact on the efficacy of chemotherapy. Myelosuppression i s associated with 80% of chemotherapy drugs, which affects therapeutic effect and prognosis in 64% of the patients. Myelosuppression significantly increases the risk of severe infection, hemorrhage, and anemia, reducing patients' quality of life and even resulting in life-threatening conditions, which also increases their financial burdens. Furthermore, myelosuppression may also lead to dose reduction or delay of chemotherapy, which has a direct impact on the therapeutic effect.
Clinically, the common approaches to resolve myelosuppression are transfusion of blood cells or infusion of various colony-stimulating factors to increase blood cell production by bone marrow hematopoietic stem/progenitor cells. However，such approaches have limitations，such as potentially leading to bone marrow depletion, with diminishing effects over long periods of time, often bring additional adverse effects such as aching in the bone. Moreover, these remedial methods can only supplement a single lineage such as white blood cell or platelet at a time, with no comprehensive prevention on myelosuppression. Patients receiving chemotherapy urgently need a treatment regimen that can work like a 'bullet proof vest', offering comprehensive protection against bone marrow damage during cancer treatment without influencing the anti-tumor effect of chemotherapy.
To meet the highly unmet clinical demand, Simcere reached an agreement with G1 therapeutics to introduce the world's first comprehensive myeloprotection drug against chemotherapy damage in the Chinese market.
"Myelosuppression induced by chemotherapy is a common toxic side effect in the clinical treatment of SCLC. There has been a huge unmet clinical need in China for an effective solution to prevent or reduce myelosuppression before it takes place," said Professor Ying Cheng , principal investigator of the Phase III pivotal trial (TRACES study) in China at Jilin Cancer Hospital. "The positive results from the TRACES study have confirmed that COSELA® provides a comprehensive protective effect against myelosuppression in Chinese patients. This product is expected to be used as part of the standard treatment regimen offered to ES-SCLC patients to reduce the toxicity and enhance the efficacy of chemotherapy.
Three published clinical studies (G1T28-05, G1T28-02, and G1T28-03) have shown that patients who received Cosela® had lower chances of experiencing severe neutropenia, Grade 3/4 anemia, or Grade 3/4 thrombocytopenia compared to patients who received a placebo, thus demonstrating its comprehensive myeloprotection effect on hematopoietic functions of neutrophils, erythrocytes, and platelets.
The research results disclosed in the abstracts at 2022 World Conference on Lung Cancer (WCLC) show that , Compared with placebo, trilaciclib resulted in clinically and statistically significant decrease in DSN in Cycle 1 (0 versus 2 days; P=0.0003). In addition, trilaciclib also significantly decreased occurrence of SN (7.3% versus 45.2%, P< 0.0001), occurrence of FN(2.4% versus 16.7%, P= 0.0267) and incidence of Grade 3 or 4 Hematologic Toxicity (53.7% versus 88.1%, P= 0.0005). Administration of trilaciclib prior to chemotherapy in ES-SCLC patients improved the patient tolerability of chemotherapy, no new safety signals were identified, and the preliminary myeloprotection effect of Trilaciclib in China study was comparable to overseas results.
First-in-Class Novel Drug Enters China
COSELA® is the world's first and only anti-tumor myeloprotection drug with a First-in-Class (FIC) mechanism. Designated as a "breakthrough therapy" by the US FDA, COSELA® received approval in the US in 2021. After establishing their strategic collaboration, Simcere and G1 therapeutics have jointly facilitated the rapid introduction of COSELA® in China .
As a highly potent, selective, and reversible CDK4/6 inhibitor, COSELA® puts CDK4/6-dependent cells, e.g., hematopoietic stem and progenitor cells (HSPCs) into temporary arrest at the G1 phase of the cell cycle, therefore reducing damage during exposure to chemotherapy. The product is expected to be used as part of the standard treatment regimen against certain cancers as an alternative to various colony-stimulating factors to increase the efficacy and reduce the toxicity of chemotherapy.
With three completed or ongoing registrational clinical trials, the product is being investigated in patients with small cell lung cancer, metastatic colorectal cancer, and triple negative breast cancer in China . The Phase III clinical trial (TRACES study) of Trilaciclib in ES-SCLC patients took only 10 months from the first Chinese IND to NDA submission, and the approval was granted by the NMPA only one year after the initial launch of the product in the US. This reflects the synergistic efficiency of global regulatory, clinical, and pharmaceutical collaboration.
Dr. Renhong Tang，Executive Director and Co-Chief Executive Officer of Simcere said: "An enormous number of patients receiving chemotherapy in China are in urgent need of safer and more effective treatment options. I wish to thank the Simcere team, our partners, and the clinical experts for their concerted efforts that facilitated the rapid development of this First-in-Class and Only-in-Class innovative product in China . Moving forward, Simcere shall continue to advance product commercialization and the expansion of other indications efficiently so as to benefit more patients sooner."
"G1 congratulates our partner Simcere on rapidly progressing the development of COSELA in Greater China and successfully obtaining marketing approval from the National Medical Products Administration," said Jack Bailey , Chief Executive Officer of G1 Therapeutics. "China is one of the largest markets globally and there remains a great unmet medical need for an effective solution to prevent or reduce the debilitating myelosuppressive side effects of chemotherapy. We are excited Simcere will now be able to make COSELA available to ES-SCLC patients in Greater China , which represents a critical initial milestone in our mission of improving the lives of those impacted by cancer globally."
COSELA® (Trilaciclib Hydrochloride for Injection) is a first-in-class comprehensive myeloprotection drug to mitigate chemotherapy-induced myelosuppression on all hematopoietic lineages. It has been approved for marketing in both China and the United States as a myeloprotective treatment administered prior to chemotherapy for extensive stage-small cell lung cancer (ES-SCLC). The product is recommended in the U.S. by two updated 2022 National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines and in China by the 2022 Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of SCLC.
In August 2020 , the Simcere reached an exclusive authorization contract with G1 to obtain COSELA®'s development and commercialization interests of all indications in Greater China . In January, April and June 2021 , three phase III clinical trials in patients with SCLC, metastatic colorectal cancer and triple negative breast cancer, were carried out in China respectively. In November 2021 , the NMPA accepted the New Drug Application (NDA) by COSELA® for registration and marketing of overseas manufactured drugs. In December 2021 , the drug was granted in the priority review. In February 2022 , the pivotal phase III clinical trials (TRACES study) reached the primary endpoint. The research results disclosed in the abstracts at 2022 World Conference on Lung Cancer (WCLC) further confirmed that administration of trilaciclib prior to chemotherapy for the treatment of patients with ES-SCLC improves the patient tolerability of chemotherapy, as demonstrated by a reduction in DSN and improved overall safety profile.
G1 is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next-generation therapies designed to improve the lives of cancer patients.
Simcere Pharmaceutical Group is an innovation and R&D-driven pharmaceutical company. It has established a National Key Laboratory of Translational Medicine and Innovative Drug Development. The Company focuses on three therapeutic areas, oncology, central nervous system and autoimmune diseases, with forward-looking layout of disease areas that may have significant clinical needs, aiming to achieve the mission of "providing today's patients with medicines of the future." Leveraging its R&D capability and commercialization excellence, the Company has built a market-leading product portfolio in China . Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading innovative companies and research institutes.
View original content:https://www.prnewswire.com/news-releases/cosela-the-worlds-first-comprehensive-myeloprotection-drug-against-chemotherapy-damage-wins-approval-in-china-301587981.html
Homeowners beware. But don't panic, either.
KEY WORDS “I think we’re giving Powell too much praise. … The last two years are one of the biggest policy mistakes in the 110-year history of the Fed by staying so easy when everything was booming.
And what it means for your wealth-building options.
On Wednesday, the Fed bumped up interest rates again, its third 75-basis point hike since June, and signaled that there could be two more such hikes by the end of this year. The conventional wisdom has the Fed acting properly, and aggressively, in an attempt to counter inflation raging at 40-year high levels. But conventional wisdom isn’t always right – and we can learn a lot by consulting the contrarians. Few top investors are more contrarian than Cathie Wood. The founder and manager of ARK Inv
You have just a few weeks to pounce on Treasury I bonds' sky-high interest rate. Also called Series I savings bonds, their interest rate is 9.62%.
Yahoo Finance's Julie Hyman discusses Tesla's vehicle recall and latest legal news.
“We printed up too much money, and just thought the party would never end,” Icahn said, adding that with the Fed raising rates to fight inflation, "the party's over."
At a companywide all-hands meeting this week, Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) chief Sundar Pichai juggled tough questions from employees regarding cuts to travel and entertainment budgets, managing productivity, and potential layoffs. Employees questioned why Google is "nickel-and-diming employees" by cutting travel and swag budgets despite record profits and substantial cash reserves as it did after the pandemic. Pichai emphasized acting responsibly to tide through such critical sit
AT&T has been crushed this year, down more than 40% from its high. But now the stock nears a key area on the charts with a 7% dividend yield.
As much as stocks are falling, moves in another financial market have even more profound implications for the global economy.
The shipping company has developed a reputation as one of the best dividend stocks around
Yahoo Finance reporter Alexandra Semenova breaks down Cathie Wood's decision to hand off her role as portfolio manager on two ETFs.
Warren Buffett’s long-term investment strategy has proven to be successful through virtually all market conditions over the past several decades – recession, high inflation and deflation. If there’s one thing that’s made Buffett one of the most successful investors in history, it’s his commitment to his strategy. A countless number of new investment techniques and algorithms have come and gone over the years, but Buffett has maintained his relatively simple strategy of picking solid companies an
Forget everything you think you know about the relationship between interest rates and the stock market.
Boeing (NYSE: BA) made a big move to put part of its troubled past behind it, but the aerospace manufacturer also apparently has fallen out of favor with what had been a key customer in China. Boeing has taken its investors on a turbulent ride over the past few years. The company's 737 MAX, which was once billed as having the potential to be the top-selling aircraft of all time, was involved in fatal crashes in 2018 and 2019 that led to the plane being grounded for 18 months and prompted a comprehensive review of Boeing's engineering and safety practices.
Word spread quickly yesterday that almost 1.1 million Tesla (NASDAQ: TSLA) vehicles were being recalled. At the morning's lows, Tesla shares were down just shy of 5%. The stock market isn't always efficient, but simple math indicates that the recall isn't the reason Tesla shares have dropped for a second straight day.
It's Friday morning -- two days after the Federal Reserve raised interest rates 0.75%, and one day after seemingly every other central bank in the world followed suit, according to The Wall Street Journal -- and oil stocks are tanking. As of 9:50 a.m. ET, shares of oil company Occidental Petroleum (NYSE: OXY) are down 5.6%, while industry bellwether ExxonMobil (NYSE: XOM) is down a solid 6%, and refiner Phillips 66 (NYSE: PSX) is leading the pack lower with a 6.7% loss.
Yahoo Finance Live anchor Seana Smith highlights stocks moving in after-hours trading, including Ford, FedEx, and Moderna.
Boise, Idaho; Philadelphia; Pensacola, Fla.; Austin; and Reno, Nev.; Minnesota; and Utah are the housing markets with the most buyer pullback, says one home builder.
(Bloomberg) -- Oil and natural gas projects that Exxon Mobil Corp. invested in between 1998 and 2017 ended up costing $138 billion more than early-stage estimates, potentially due to mismanagement by operators and poor planning, according to an internal analysis seen by Bloomberg.Most Read from BloombergBank of England Says Paper Banknotes Only Good for One More WeekRisk Assets Crushed With Few Signs Drama Is Over: Markets WrapJapan to Restore Visa-Free Travel From Oct. 11 as Covid Pandemic Rece